Pluri Inc. (PLUR)
| Market Cap | 13.63M -66.2% |
| Revenue (ttm) | 1.08M +4.4% |
| Net Income | -25.54M |
| EPS | -2.83 |
| Shares Out | 10.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,634 |
| Open | 1.260 |
| Previous Close | 1.270 |
| Day's Range | 1.250 - 1.260 |
| 52-Week Range | 1.250 - 5.174 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About PLUR
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle inj... [Read more]
Financial Performance
In fiscal year 2025, Pluri's revenue was $1.34 million, an increase of 309.82% compared to the previous year's $326,000. Losses were -$22.58 million, 8.11% more than in 2024.
Financial StatementsNews
Pluri prices 2.23M shares at $1.50 in registered direct offering
Pluri (PLUR) announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 common shares at a…
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform ...
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic ce...
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader ...
Pluri announces chairman Alejandro Weinstein ownership surpasses 30%
Pluri (PLUR) provided an update on the cumulative investment and ownership position of its chairman, Alejandro Weinstein. The company said, “Over the past year, Mr. Weinstein has invested more than…
Plurilock Announces Results of Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecu...
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics marke...
Pluri announces additional $2.5M investment from Alejandro Weinstein
Pluri (PLUR) announced that an entity beneficially owned by Alejandro Weinstein, chairman of the board and one of the company’s largest shareholders, has entered into a securities purchase agreement w...
Pluri secures global IP position with CNIPA for immune cell expansion
Pluri (PLUR) announces that the China National Intellectual Property Administration, CNIPA, has granted Pluri Biotech, a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune c...
Pluri completes first phase of program with Resbiomed Technologies OOD
Pluri (PLUR) announced the completion of the first phase of its program with Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix-based biomaterials and biologi...
Pluri announces expansion of manufacturing agreement with Remedy Cell
Pluri (PLUR) announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Ma...
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-b...
Pluri appoints Weinstein as Chairman of the Board of Directors
Pluri (PLUR) announced that Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the Board of Directors. The company said the “appointment reflects the Board’...
Pluri announces launch of Cellav Health and Aesthetics
Pluri (PLUR) announces the launch of Cellav Health and Aesthetics, its wholly-owned health and aesthetics subsidiary, focused on developing science-driven and regenerative solutions powered by Pluri’s...
Pluri enters series of international collaborations
Pluri (PLUR) entered into a series of significant international collaborations across its foodtech and agtech subsidiaries. These collaborations represent a major step forward in Pluri’s mission to tr...
Pluri subsidiary Coffeesai announces strategic collaboration for manufacturing
Pluri (PLUR) announced that Coffeesai, its wholly owned subsidiary developing sustainable cell-based coffee products, has signed an agreement with the Instituto del Cafe de Chiapas, a public body of t...
Pluri files to sell 3.425M common shares for holders
17:29 EDT Pluri (PLUR) files to sell 3.425M common shares for holders
Pluri re-initiated with a Buy at Alliance Global Partners
Alliance Global Partners analyst Matthew Venezia re-initiated coverage of Pluri (PLUR) with a Buy rating and $12 price target The company has transitioned from a clinical-stage cell therapy biotech wi...
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has s...
Pluri CEO issues letter to shareholders
Pluri (PLUR) issued the following shareholder update from Chief Executive Officer and President, Yaky Yanay: “As we conclude our fiscal year, which was marked by challenges and accomplishments, I’m pl...
Pluri completes strategic acquisition of 71% of equity of Kokomodo for $4.5M
Pluri (PLUR) announced the completion of the acquisition of approximately 71% of the equity of Kokomodo for $4.5 million payable in 976,139 of the Company’s Common Shares. Kokomodo will continue…
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.
Pluri announces USPTO issued patent covering its immune cell expansion tech
Pluri (PLUR) announced that the U.S. Patent and Trademark Office, USPTO, has issued a patent covering the Company’s immune cell expansion technologies. This patent specifically includes MAIT cells, a ...
Pluri announces exclusive collaboration agreement with Hemafund
Pluri (PLUR) announced that it has signed an exclusive collaboration agreement with Hemafund, a Ukrainian umbilical cord blood bank with clinical and research laboratories and facilities specializing ...
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
Strategic initiative to address Ukraine's urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may pote...